Table 1.
Clinical and demographic characteristics of included patients n (%)
| CD | UC | IBS | |
| Number of patients, n | 92 | 44 | 25 |
| Male | 54 (58.7) | 26 (59.1) | 11 (44) |
| Median age at test (range) | 29.5 (18-62) | 38 (19-70) | 35 (21-52) |
| Age at diagnosis (yr) | NA | ||
| A1 (< 16) | 7 (7.6) | 2 (4.5) | |
| A2 (17-40) | 69 (75.0) | 27 (61.4) | |
| A3 (> 40) | 16 (17.4) | 15 (34.1) | |
| Disease location | NA | ||
| Ileum (L1) | 22 (23.9) | NA | |
| Colonic (L2) | 10 (10.9) | NA | |
| Ileum-Colonic (L3) | 60 (65.2) | NA | |
| Upper GI (L4) | 9 (9.8) | NA | |
| Rectum (E1) | NA | 15 (34.1) | |
| Distal colitis (E2) | NA | 14 (31.8) | |
| Extensive colitis (E3) | NA | 15 (34.1) | |
| Concomitant medications1 | NA | ||
| No medication | 9 (9.8) | 3 (6.8) | |
| 5-ASA | 28 (30.4) | 37 (84.1) | |
| Corticosteroids | 22 (23.9) | 9 (20.5) | |
| Immunosuppressants | 39 (42.4) | 1 (2.31) | |
| Anti-TNF therapy | 36 (39.1) | 4 (9.1) | |
| Previous IBD-related surgery: no/yes | 69/23 | NA | NA |
1
Because therapy regimens overlapped, the total is not 100%. GI: Gastrointestinal; ASA: 5-aminosalicylic acid; TNF: Tumor necrosis factor; NA: Not applicable; IBS: Irritable bowel syndrome; CD: Crohn’s disease; UC: Ulcerative colitis.